Research Analysts Offer Predictions for WVE FY2028 Earnings

Wave Life Sciences Ltd. (NASDAQ:WVE) – Equities research analysts at HC Wainwright raised their FY2028 earnings per share (EPS) estimates for Wave Life Sciences in a report issued on Wednesday, November 13th. HC Wainwright analyst A. Fein now forecasts that the company will earn $1.27 per share for the year, up from their previous forecast of $1.23. HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.09) per share.

WVE has been the subject of a number of other research reports. Leerink Partners lifted their price target on shares of Wave Life Sciences from $20.00 to $22.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 16th. Wells Fargo & Company increased their price target on shares of Wave Life Sciences from $11.00 to $22.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 16th. Raymond James upgraded Wave Life Sciences from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $13.00 to $22.00 in a research report on Wednesday, October 16th. B. Riley upped their price target on Wave Life Sciences from $19.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, November 4th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Wave Life Sciences from $13.00 to $17.00 and gave the stock an “overweight” rating in a report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Wave Life Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $21.89.

Wave Life Sciences Stock Performance

Shares of NASDAQ:WVE opened at $13.67 on Friday. Wave Life Sciences has a one year low of $3.50 and a one year high of $16.74. The business’s 50-day simple moving average is $10.76 and its 200 day simple moving average is $7.54. The company has a market cap of $2.08 billion, a P/E ratio of -12.32 and a beta of -1.20.

Insider Buying and Selling

In other news, CEO Paul Bolno sold 51,234 shares of Wave Life Sciences stock in a transaction on Friday, November 15th. The stock was sold at an average price of $14.32, for a total transaction of $733,670.88. Following the completion of the sale, the chief executive officer now owns 217,351 shares of the company’s stock, valued at approximately $3,112,466.32. This trade represents a 19.08 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Chris Francis sold 36,000 shares of the stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $576,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 452,056 shares of company stock valued at $5,955,438. 29.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC increased its stake in shares of Wave Life Sciences by 14.3% in the third quarter. Geode Capital Management LLC now owns 2,269,664 shares of the company’s stock worth $18,615,000 after purchasing an additional 283,419 shares in the last quarter. Barclays PLC lifted its stake in Wave Life Sciences by 171.1% during the third quarter. Barclays PLC now owns 159,241 shares of the company’s stock worth $1,307,000 after purchasing an additional 100,498 shares during the last quarter. Orion Portfolio Solutions LLC purchased a new stake in Wave Life Sciences in the third quarter worth approximately $123,000. XTX Topco Ltd bought a new position in shares of Wave Life Sciences during the 3rd quarter valued at $126,000. Finally, Jane Street Group LLC increased its holdings in shares of Wave Life Sciences by 33.3% in the third quarter. Jane Street Group LLC now owns 142,014 shares of the company’s stock worth $1,165,000 after buying an additional 35,472 shares during the period. Hedge funds and other institutional investors own 89.73% of the company’s stock.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.